ALNY · Alnylam Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $1.25B | $773.69M | $594.19M | - | $500.92M | $659.83M | $494.33M | - | $264.31M |
| Cost of Revenue | - | $197.23M | $142.03M | $70.18M | - | $81.98M | $67.27M | $54.61M | - | $79.47M |
| Gross Profit | - | $1.05B | $631.66M | $524.01M | - | $418.94M | $592.55M | $439.72M | - | $184.83M |
| R&D | - | $358.81M | $323.62M | $265.12M | - | $270.93M | $294.14M | $261.00M | - | $253.18M |
| SG&A | - | $322.08M | $323.31M | $239.95M | - | $220.99M | $248.40M | $210.80M | - | $199.18M |
| Total Operating Expenses | - | $881.04M | $789.89M | $576.11M | - | $577.82M | $611.21M | $537.77M | - | $536.66M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | $367.98M | ($16.20M) | $18.08M | - | ($76.91M) | $48.61M | ($43.44M) | - | $213.87M |
| Interest Expense | - | $44.40M | $40.25M | $35.25M | - | $34.38M | $30.04M | $35.25M | - | $30.89M |
| Income Tax | - | ($12.12M) | $30.92M | $15.88M | - | $2.91M | $5.72M | $2.35M | - | $2.99M |
| Net Income | - | $251.08M | ($66.28M) | ($57.48M) | - | ($111.57M) | ($16.89M) | ($65.94M) | - | $147.75M |
| EPS - Basic | - | $1.91 | ($0.51) | ($0.44) | - | ($0.87) | ($0.13) | ($0.52) | - | $1.18 |
| EPS - Diluted | - | $1.84 | ($0.51) | ($0.44) | - | ($0.87) | ($0.13) | ($0.52) | - | $1.15 |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $1.49B | $1.11B | $1.02B | $966.43M | $1.10B | $968.49M | $681.88M | $812.69M | $1.03B |
| Accounts Receivable | $777.57M | $964.77M | $567.11M | $418.04M | $405.31M | $353.85M | $309.48M | $321.38M | $327.79M | $325.44M |
| Inventory | $82.72M | $75.38M | $71.69M | $65.58M | $78.51M | $75.99M | $83.98M | $93.99M | $89.15M | $95.77M |
| Accounts Payable | $115.72M | $117.59M | $102.39M | $97.40M | $88.42M | $70.81M | $73.98M | $78.15M | $55.52M | $73.84M |
| Current Assets | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | $2.98B | $2.99B |
| Total Assets | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B | $3.84B |
| Current Liabilities | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $941.71M | $967.79M | $949.78M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | $4.05B | $4.00B |
| Stockholders' Equity | $789.18M | $233.89M | $250.59M | $115.44M | $67.09M | $32.35M | ($3.07M) | ($219.27M) | ($220.64M) | ($165.87M) |
| Retained Earnings | ($6.70B) | ($7.16B) | ($7.41B) | ($7.35B) | ($7.29B) | ($7.20B) | ($7.09B) | ($7.08B) | ($7.01B) | ($6.87B) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($118.31M) | - | - | - | ($81.52M) | - | - |
| Investing Cash Flow | - | - | - | $113.77M | - | - | - | ($67.62M) | - | - |
| Financing Cash Flow | - | - | - | $44.08M | - | - | - | $28.91M | - | - |
| CapEx | - | - | - | $8.97M | - | - | - | $12.97M | - | - |
| Free Cash Flow | - | - | - | ($127.28M) | - | - | - | ($94.49M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 84.2% | 81.6% | 88.2% | - | 83.6% | 89.8% | 89.0% | - | 69.9% |
| Operating margin | - | 29.5% | -2.1% | 3.0% | - | -15.4% | 7.4% | -8.8% | - | 80.9% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | 20.1% | -8.6% | -9.7% | - | -22.3% | -2.6% | -13.3% | - | 55.9% |
| Free cash flow margin | - | - | - | -21.4% | - | - | - | -19.1% | - | - |
| FCF / Net income | - | - | - | 2.21 | - | - | - | 1.43 | - | - |
| R&D / Revenue | - | 28.7% | 41.8% | 44.6% | - | 54.1% | 44.6% | 52.8% | - | 95.8% |
| SG&A / Revenue | - | 25.8% | 41.8% | 40.4% | - | 44.1% | 37.6% | 42.6% | - | 75.4% |
| Effective tax rate | - | -5.1% | - | - | - | - | - | - | - | 2.0% |
| Return on assets | - | 5.2% | -1.5% | -1.4% | - | -2.7% | -0.4% | -1.7% | - | 3.8% |
| Return on equity | - | 107.3% | -26.4% | -49.8% | - | -344.8% | 550.7% | 30.1% | - | -89.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.76 | 2.54 | 2.80 | 3.04 | 2.78 | 2.75 | 3.01 | 3.17 | 3.08 | 3.14 |
| Quick ratio | 2.71 | 2.49 | 2.75 | 2.98 | 2.71 | 2.69 | 2.93 | 3.07 | 2.99 | 3.04 |
| Cash ratio | 1.13 | 0.96 | 0.86 | 0.95 | 0.81 | 0.90 | 0.92 | 0.72 | 0.84 | 1.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | 8.3x | -0.4x | 0.5x | - | -2.2x | 1.6x | -1.2x | - | 6.9x |
| Equity multiplier | 6.29 | 20.74 | 18.22 | 36.50 | 63.20 | 129.97 | -1307.35 | -17.44 | -17.36 | -23.15 |
| Liabilities / Assets | 0.84 | 0.95 | 0.95 | 0.97 | 0.98 | 0.99 | 1.00 | 1.06 | 1.06 | 1.04 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.26 | 0.17 | 0.14 | - | 0.12 | 0.16 | 0.13 | - | 0.07 |
| Inventory turnover | - | 2.62 | 1.98 | 1.07 | - | 1.08 | 0.80 | 0.58 | - | 0.83 |
| Days sales outstanding | - | 282d | 268d | 257d | - | 258d | 171d | 237d | - | 449d |
| Days inventory outstanding | - | 140d | 184d | 341d | - | 338d | 456d | 628d | - | 440d |
| Days payable outstanding | - | 218d | 263d | 507d | - | 315d | 401d | 522d | - | 339d |
| Cash conversion cycle | - | 204d | 189d | 91d | - | 281d | 225d | 343d | - | 550d |
| Valuation | ||||||||||
| P / E | - | 247.8x | - | - | - | - | - | - | - | 154.0x |
| P / B | - | 267.8x | 170.0x | 303.3x | - | 1093.1x | - | - | - | - |
| P / S | - | 50.1x | 55.1x | 58.9x | - | 70.6x | 46.7x | 38.1x | - | 88.0x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 149.3% | 17.3% | 20.2% | - | 89.5% | 107.0% | 131.8% | - | 0.0% |
| Revenue CAGR (3y) | - | 67.8% | 51.0% | 40.7% | - | 38.7% | 44.1% | 40.7% | - | 28.1% |
| Revenue CAGR (5y) | - | 58.2% | 49.4% | 43.0% | - | 48.2% | 71.3% | 71.5% | - | 72.9% |
| Gross profit growth (YoY) | - | 151.1% | 6.6% | 19.2% | - | 126.7% | 143.4% | 155.9% | - | -18.9% |
| Operating income growth (YoY) | - | - | - | - | - | - | - | 71.0% | - | - |
| Net income growth (YoY) | - | - | -292.4% | 12.8% | - | - | 93.9% | 62.1% | - | - |
| EPS growth (YoY) | - | - | -292.3% | 15.4% | - | - | 94.1% | 62.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -34.7% | - | - | - | 47.6% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1076.3% | 622.9% | - | - | - | - | 99.2% | 15.4% | -39.5% | -145.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$9.58B totalProduct$2.99B · 31.2%
TTR$2.49B · 26.0%
Amvuttra$1.73B · 18.1%
Collaborations$553.37M · 5.8%
Rare$499.92M · 5.2%
License Obligation$300.00M · 3.1%
License$300.00M · 3.1%
GIVLAARI$205.72M · 2.1%
Royalty$174.02M · 1.8%
Development Services Obligation$89.00M · 0.9%
OXLUMO$68.47M · 0.7%
ONPATTRO$62.13M · 0.6%
Other License Programs$50.37M · 0.5%
Research Services Obligation$39.52M · 0.4%
C5 License Obligation$21.64M · 0.2%
Product And Service Other$5.88M · 0.1%
Regeneron Technology Transfer Obligation$2.43M · 0.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ALNYLAM PHARMACEUTICALS against the 5 most active filers in the same SIC group.